- Company
- Leclaza’s sales soar with reimbursement expansion
- by Chon, Seung-Hyun May 23, 2024 05:48am
- The sales of Yuhan Corp’s new anti-cancer drug 'Leclaza' have jumped significantly. Sales have more than tripled in one year since the drug has been granted reimbursement as a first-line treatment for lung cancer this year. Leclaza’s sales quickly reached the KRW 20 billion mark in quarterly sales, paving the way for the drug to achieve the KR
- Company
- Oral renal anemia drug meets reimb listing terms
- by Nho, Byung Chul May 22, 2024 05:47am
- An application for drug pricing has been filed for two items of renal anemia drugs that are equivalent in efficacy to conventional EPO injections but cost much less. New treatment options are expected to become available. According to industry sources, Mitsubishi Tanabe Pharma and JW Pharmaceutical have filed an application to the Heal
- Company
- MSD applies for Welireg’s reimbursement in Korea
- by Eo, Yun-Ho May 22, 2024 05:47am
- The rare anti-cancer drug ‘Welireg’is seeking insurance coverage in Korea. According to industry sources, MSD Korea recently submitted an application for the reimbursement of its oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor Welireg (belzutifan). The drug is beginning its reimbursement voyage a year after its approval in Kor
- Company
- FDA approves Samsung and Biocon’s Eylea biosimilars
- by Son, Hyung-Min May 22, 2024 05:47am
- Samsung Bioepis’s Opuviz became the first Eylea biosimilar to be approved in the US. In particular, due to its interchangeability designation, Opuviz can be administered interchangeably with Eylea, increasing its chances of gaining an advantage in the market over its competitors. According to KoreaBIO on the 21st, the US FDA approved Sam
- Company
- FDA approval delayed and retry…what’s 'Rivoceranib'?
- by Son, Hyung-Min May 21, 2024 05:56am
- HLB’s rivoceranib, which was expected to be an FDA-approved new drug candidate, failed to receive final approval. Although HLB confirmed that Rivoceranib combined with immunotherapy camrelizumab extended overall survival in the first-line treatment for liver cancer, they received request for supplementary documents. The current request f
- Company
- Flu drug market enjoys rise for 6 consecutive quarters
- by Chon, Seung-Hyun May 21, 2024 05:56am
- The outpatient prescription market for flu drugs has recovered. Their prescription market, which had remained almost nonexistent for 3 years after the COVID-19 pandemic, has expanded significantly since then. With the flu epidemic lasting more than a year, the market for flu treatments has returned to pre-pandemic levels. According to the mar
- Company
- Series of drug patent expiries change ₩250B DOAC mkt
- by Moon, sung-ho May 21, 2024 05:55am
- The direct oral anti-coagulant (DOAC) market is changing shape at an accelerated pace. This is due to the series of patent expiries of original drugs that had recorded high sales, mainly in the cardiology departments of university hospitals and clinic-level medical centers. In particular, with the accelerated entry of generic drugs (g
- Company
- Rolvedon's cumulative US sales surpasses ₩100B
- by Son, Hyung-Min May 21, 2024 05:55am
- Hanmi Pharmaceutical's neutropenia drug Rolvedon is cruising in the US market. Rolvedon has surpassed KRW 100 billion in cumulative sales in the US market. Hanmi Pharmaceutical's U.S. partner Assertio plans to further increase the drug’s market share by securing a same-day dosing indication. According to Assertio on the 18th, Rolvedon genera
- Company
- Dong-A, Ildong join hands…R&D synergy and resources
- by Chon, Seung-Hyun May 21, 2024 05:55am
- Dong-A ST and Idience join hands to develop novel anticancer drugs. Dong-A ST invested KRW 25 billion in Ildong’s subsidiary, Idience, and will co-develop novel anticancer drugs. Consequently, Dong-A ST has secured a pipeline of potential novel anticancer drugs, and Idience successfully contracted investment for its novel drug development.
- Company
- Global RSV vaccines emerge…K-pharma enters clinical trials
- by Son, Hyung-Min May 20, 2024 05:42am
- Competition is expected to intensify as new drugs emerge in the respiratory syncytial virus (RSV) market. Sanofi received approval for its RSV vaccine and is the third company to acquire the approval, following GSK and Pfizer. Furthermore, Moderna’s messenger RNA (mRNA) vaccine awaits the FDA approval. In South Korea, EuBiologics has ente
